Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tirofiban. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 known ✓ | P05106 | 20/20 | 0.98 |
| ▸ | ITGA2B known ✓ | P08514 | 20/20 | 0.98 |
| ▸ | ITGAV | P06756 | 2/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tirofiban SCHEMBL41327 | 1.00 | ITGB3 (0.98) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| Tirofiban SCHEMBL7388934 | 0.99 | ITGB3 (0.96) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| Tirofiban SCHEMBL41325 | 0.99 | ITGB3 (0.96) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| Tirofiban SCHEMBL17721319 | 0.99 | ITGB3 (1.00) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| Tirofiban SCHEMBL3685 | 0.99 | ITGB3 (1.00) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| Tirofiban SCHEMBL618214 | 0.99 | ITGB3 (1.00) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| Tirofiban SCHEMBL28858023 | 0.98 | ITGB3 (0.98) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| Tirofiban SCHEMBL140366 | 0.97 | ITGB3 (0.96) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| Tirofiban SCHEMBL41326 | 0.96 | ITGB3 (0.95) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL13873863 | 0.90 | ITGB3 (0.83) | ITGB3ITGA2BITGAVCHRM2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102875449-A | Separation method for tirofiban hydrochloride isomer, and metering method for D-configuration tirofiban hydrochloride | TIANJIN NANKAI SHARE PHARMACEUTICAL TECHNOLOGY CO LTD | 2013-01-16 | — | — | CN | claimed |
| EP-1061908-A4 | COMBINATION THERAPY AND COMPOSITION FOR ACUTE CORONARY ISCHEMIC SYNDROME AND RELATED CONDITIONS | MERCK & CO INC (US) | 2007-01-24 | — | — | EP | claimed |
| EP-0946178-A4 | COMBINATION THERAPY FOR REDUCING THE RISKS ASSOCIATED WITH CARDIOVASCULAR DISEASE | MERCK & CO INC (US) | 2003-05-07 | — | — | EP | claimed |
| EP-0939900-A4 | DETECTION OF ANTAGONIST-DEPENDENT GPIIb/IIIa RECEPTOR ANTIBODIES | MERCK & CO INC (US) | 2003-01-08 | — | — | EP | claimed |
| US-20020009753-A1 | Anticoagulant test | BEDNAR BOHUMIL (US) | 2002-01-24 | — | — | US | claimed |
| US-20010036913-A1 | Combination therapy for reducing the risks associated with cardiovascular disease | GOULD ROBERT J (US) | 2001-11-01 | — | — | US | claimed |
| US-6235706-B1 | Combination therapy for reducing the risks associated with cardiovascular disease | MERCK & CO., INC. | 2001-05-22 | — | — | US | claimed |
| EP-0709085-B1 | Sustained-release preparation | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-01-31 | — | — | EP | claimed |
| EP-1061908-A1 | COMBINATION THERAPY AND COMPOSITION FOR ACUTE CORONARY ISCHEMIC SYNDROME AND RELATED CONDITIONS | Merck & Co., Inc. (US) | 2000-12-27 | — | — | EP | claimed |
| US-6136804-A | ANTIISCHEMIC AGENTS, ANTITHROMBOTIC AGENTS, THROMBOTIC OCCLUSION AND ANTIPLATELET AGENT | MERCK & CO., INC. (US) | 2000-10-24 | — | — | US | claimed |
| EP-0946178-A1 | COMBINATION THERAPY FOR REDUCING THE RISKS ASSOCIATED WITH CARDIOVASCULAR DISEASE | Merck & Co., Inc. (US) | 1999-10-06 | — | — | EP | claimed |
| WO-1999045913-A1 | COMBINATION THERAPY AND COMPOSITION FOR ACUTE CORONARY ISCHEMIC SYNDROME AND RELATED CONDITIONS | MERCK & CO., INC. (US) | 1999-09-16 | — | — | WO | claimed |
| EP-0939900-A1 | DETECTION OF ANTAGONIST-DEPENDENT GPIIb/IIIa RECEPTOR ANTIBODIES | Merck & Co., Inc. (US) | 1999-09-08 | — | — | EP | claimed |
| EP-0743302-B1 | Sulfonamide fibrinogen receptor antagonists | MERCK & CO INC (US) | 1999-08-04 | — | — | EP | claimed |
| WO-1998022821-A1 | DETECTION OF ANTAGONIST-DEPENDENT GPIIb/IIIa RECEPTOR ANTIBODIES | MERCK & CO., INC. (US) | 1998-05-28 | — | — | WO | claimed |
| WO-1998011896-A1 | COMBINATION THERAPY FOR REDUCING THE RISKS ASSOCIATED WITH CARDIOVASCULAR DISEASE | MERCK & CO., INC. (US) | 1998-03-26 | — | — | WO | claimed |
| WO-1997035579-A1 | A METHOD FOR INHIBITING CLOT FORMATION | MERCK & CO., INC. (US) | 1997-10-02 | — | — | WO | claimed |
| WO-1997035615-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CLOT FORMATION | MERCK & CO., INC. (US) | 1997-10-02 | — | — | WO | claimed |
| EP-0478363-B1 | Novel sulfonamide fibrinogen receptor antagonists | MERCK & CO INC (US) | 1997-03-19 | — | — | EP | claimed |
| EP-0743302-A2 | Sulfonamide fibrinogen receptor antagonists | MERCK & CO. INC. (US) | 1996-11-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010036913-A1 | Combination therapy for reducing the risks associated with cardiovascular disease | HMGCR, PCSK9, APOB | ITGB3 699/4885ITGA2B 740/4885ITGAV 767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.